This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions. The PD-1/PD-L1 inhibitor and TCR/CAR-T therapy drug classes lead development of all immuno-oncology drugs. However, several novel mechanisms of action are also in early-phase development.

This Datamonitor Healthcare Disease report focuses on the field of immuno-oncology.